NEWSpublisher 2007 :: AngloChinese Investments
SEARCH NEWS
date from:
date to:
company:
search for string:
NEWS SECTIONS
COMPANY GROUPS
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS » ACTIVITIES ENGAGED IN: Ingredients  1  2  3  4  5  » 
found files: 251
AstraZeneca »17/02/2007 [Company watch]
AstraZeneca Wins 2nd Award for Investment in China

Following $134millions investment in a manufacturing plant at Wuxi in 2001, AZ have announced a further $35millions investment in the site. In May 2006 AZ announced its intention to invest $100millions in R & D in China....   more»


Novartis »11/02/2007 [Company watch]
Novartis to focus on Hepatitus drugs in China

Novartis will launch a product for hepatitus B this year as it is China\\\'s prevalent disease with approx 20 million affected. CEO Vasella says they have been growing by 20% on average over the last 5 years and gained considerable market share....   more»


Novo Nordisk »05/03/2007 [Company watch]
Novo Nordisk and Chinese Academy of Science establish Research Foundation

Novo Nordisk have committed $2million to co-fund research activities of mutual interest - diabetes and biopharmaceuticals....   more»


Charles River »23/03/2007 [Company watch]
Charles River commits to large expansion programme in Shanghai

Charles River Laboratories International, Inc. (NYSE:CRL) announced today the expansion of its global footprint in Asia as part of its strategy to support customers' research and development efforts in this rapidly growing market....   more»


AstraZeneca »23/03/2007 [Company watch]
AStraZeneca name site for lab expansion plan

AStrazeneca confirm site for their $100Million R & D expansion in China as the Zhangjiang Hi-Tech park in Shanghai with completion due in mid 2007. Recruitrment of scientists is already underway. The Innovation Center China will open in mid-2007 before the establishment of a permanent site that officials are still looking for....   more»


NCCSED »06/03/2007 [Industry news]
Frontier links with NCCSED (CRO) in China

US based Frontier Biosciences has signed agreement with National Chengdu Centre for Safety Evaluation of Drugs - a full service pre-clinical CRO regarded as one of the best in China - established by West China Hospital of the Sichuan University...   more»


Wuxi Pharma Tech »07/04/2007 [Industry news]
WuXi PharmaTech Sets Up Life Science and Chemistry Award

WuXi PharmaTech, China's leading provider of pharmaceutical outsourcing services is pleased to announce the establishment of the "WuXi PharmaTech Life Science and Chemistry Award"; worth one million RMB. The award will honor individuals and groups who make a significant contribution to the fields of life science and chemistry in China....   more»


AstraZeneca »24/04/2007 [Company watch]
AStra Zeneca are advertising for :TRANSLATIONAL SCIENTIST for pre-clinical development in cancer research

AStra Zeneca are seeking an experienced scientist to lead pre clinical cancer trials team in the Shanghai Innovation Centre - full job advert below, to be fully operational by 2009...   more»


Novo Nordisk »03/05/2007 [Company watch]
Novo Nordisk will continue to exploit the emerging importance of China in pharma research by establishing a new diabetes research foundation there.

UPDATE: The Danish pharma company is setting up a joint science research foundation with the Chinese Academy of Science (CAS). The collaboration will concentrate on diabetes and biopharmaceuticals research, including related fields and technologies such as protein chemistry, immunology, inflammation, toxicology, oncology and drug delivery....   more»


Simcere Pharmaceutical Group »19/04/2007 [Finance]
Simcere Pharmaceutical Group Announces Pricing of Initial Public Offering on NYSE

Simcere Pharmaceutical Group, a leading manufacturer and supplier of branded generic pharmaceuticals in the rapidly growing China market, announced today that its initial public offering of 15,625,000 American Depositary Shares (ADSs), each representing two ordinary shares, was priced at an initial public offering price of $14.50 per ADS. The ADSs will begin trading on the New York Stock Exchange on April 20, 2007 under the symbol ''SCR.''...   more»


Shanghai ChemPartner Co.,Ltd. »25/04/2007 [Company watch]
Biotage, Chempartner sign multi-instrument deal

Shanghai Chempartner Co., Ltd., one of China‚Äôs leading contract research organizations (CRO), has invested in Biotage SP automated flash instruments and Initiator microwave synthesizers with delivery scheduled over the next 12 months. This is Biotage's largest single order in China at a value of $1.48 m....   more»


Charles River »08/05/2007 [Company watch]
Charles River announces 1st Quarter 2007 results

see full report...   more»


Charles River »24/04/2007 [Company watch]
Charles River Laboratories Appoints Cheri Walker, Ph.D. as Corporate Senior Vice President, Corporate Development

Charles River Laboratories International, Inc. (NYSE: CRL) announced today the appointment of Cheri Walker, Ph.D. to the role of Corporate Senior Vice President, Corporate Development, effective April 24, 2007. Dr. Walker will be responsible for the Company's global corporate development function, directing all aspects of our merger, acquisition and strategic joint venture activities. She will also participate as an integral member in the strategic planning process of the Company. Prior to joining Charles River, Dr. Walker was Vice President, Mergers and Acquisitions for QIAGEN Sciences where she oversaw the corporate development of QIAGEN's North American life sciences tools and molecular diagnostics businesses. Previously, Dr. Walker held senior corporate development and operational positions at Invitrogen where she successfully executed acquisition and licensing transactions. James C. Foster, Chairman, President and Chief Executive Officer of Charles River Laboratories noted, "We are delighted to have Cheri join the Charles River team. Her depth of experience in life science transactions adds greater strength to our management team." Dr. Walker commented, "I have followed the growth of Charles River for several years and am very excited to be joining a dynamic and expanding company. Corporate Development will play an integral role in this growth and I am looking forward to being part of the team." Dr. Walker holds a doctorate in Human and Molecular Genetics from Baylor College of Medicine and a bachelor's degree in Biology from Swarthmore College....   more»


Novartis »23/04/2007 [Company watch]
Novartis with dynamic growth in the 2007 first quarter

Strong 2007 first quarter performance as Group net sales advance 18% (+15% in local currencies) to USD 9.8 billion on excellent performances from all divisions Group continuing operations operating income up 18%, net income up 17%...   more»


Eli Lilly & Co »04/05/2007 [Company watch]
Lilly Announces Senior Leadership Changes

Alex M. Azar II to join Lilly as senior vice president of corporate affairs and communications; Anne Nobles to assume role of chief compliance officer...   more»


Eli Lilly & Co »16/04/2007 [Company watch]
Lilly Reports Strong First-Quarter Results; Raises Full-Year Sales and EPS Guidance

Eli Lilly and Company (NYSE: LLY) today announced strong financial results for the first quarter of 2007 and raised its full-year sales and adjusted earnings per share guidance. First-Quarter Highlights * Sales increased 14 percent, to $4.226 billion....   more»


Simcere Pharmaceutical Group »03/06/2007 [Industry news]
Simcere Pharmaceutical Group is looking to build its future on research

Flush with cash from its US IPO, Simcere Pharmaceutical Group is looking to build its future on research. Late last month, Simcere weighed in with the largest IPO on the New York Stock Exchange for an Asian pharmaceutical company, raising 261 mln usd. Now it plans to put some of that money to work. 'We need to consider both the long-term and the short-term,' said Jinsheng Ren, chairman and CEO. 'Pharmaceutical technology can really set companies apart in China and that is why we say R & D is our focus.' "THIS HIGHLY RESPECTED COMPANY COULD BE A GOOD PARTNER FOR HLS"...   more»


Eli Lilly & Co »06/06/2007 [Company watch]
BioVeda China to Receive $10 Million Investment from Lilly Asian Ventures

BioVeda China today announced a $10 Million investment from Lilly Asian Ventures. BioVeda China is the first international venture capital fund focusing on life-sciences investments in China. The investment has shown Lilly's commitment to expand its economic footprint in the fast growing life-science industry in China....   more»


Sundia MediTech Company,Ltd. »06/06/2007 [Company watch]
China CROs Merge

Sundia MediTech and Shanghai United PharmaTech report that they will be merging. This is a first for China‚Äôs young CRO industry, acording to Sundia‚Äôs CEO, Wang Xiaochuan, Ph.D. Both Xiaochuan and United PharmaTech‚Äôs CEO, Shi Xiongwei, Ph.D., signed a letter of intent agreeing to combine their two companies. Under the terms of the merger, both United PharmaTech and Sundia MediTech will become subsidiaries of Sundia Investment Group, the British Virgin Islands-based holding company that currently owns Sundia MediTech. Dr. Wang will become the new company‚Äôs chairman and CEO, while Dr. Shi will hold the positions of director and executive vp. The former senior management teams of both companies will join together into a new, combined management team. Zhang Suyang, a partner of IDG VC, said that he believes China‚Äôs drug development CRO industry is beginning to emerge from its initial state into one in which companies will begin to consolidate. ‚ÄúThe CRO companies, and the overall size of the CRO industry in China are still relatively small, and there is huge potential for growth, so we can expect that in the following few years there will be many mergers,‚ÄĚ explained Zhang. ‚ÄúCompanies in this industry will grow quickly and soon; we will see companies of reasonable size and with good governance emerge as corporations with serious long-term potential.‚ÄĚ Part of the reason for the merger, noted Dr. Wang, is that it will combine United PharmaTech‚Äôs and Sundia‚Äôs technical expertise in different fields....   more»


Eli Lilly & Co »07/06/2007 [Company watch]
Lilly Announce $100 Million Investment in Research in China

Eli Lilly & Co, one of the world's leading pharmaceutical firms, plans to pour $100 million into China over the next five years to expand its drug research capacity in a bid to tap into the country's talent pool, its CEO said. The US drug maker will primarily beef up its research and development in biology, chemistry and clinical research areas, said John Lechleiter, president and CEO of Eli Lilly & Co....   more»

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.